share_log

CB Scientific Files Application to Uplist to the OTCQB Venture Market

CB Scientific Files Application to Uplist to the OTCQB Venture Market

世邦魏理仕科技档案申请提升OTCQB创业市场
Accesswire ·  2021/11/16 06:06

Upgraded listing would provide increased transparency and enhanced trading efficiency

升级后的上市将提高透明度和交易效率。

ESCONDIDO, CA / ACCESSWIRE / November 16, 2021 / CB Scientific. Inc. (OTC PINK:CBSC) ("CBSC" or the "Company") is pleased to announce that it has submitted its application to uplist to the OTCQB® Venture Market.

加利福尼亚州埃斯孔迪多/ACCESSWIRE/2021年11月16日/CB Science.Inc.(场外粉色:CBSC)CBSC(以下简称“CBSC”或“本公司”)很高兴地宣布,它已经提交了在OTCQB®创业板市场上市的申请。

The application itself is not a guarantee of acceptance by OTC MARKETS to go from the Company's current OTC PINK status to uplisting onto the OTCQB®. However, CB Scientific previously engaged MaloneBailey LLP to conduct a Public Company Accounting Oversight Board (PCAOB) audit and has appointed sufficient independent directors, both key requirements to be considered for uplisting.

申请本身并不保证场外市场接受该公司目前的场外粉色状态升级到OTCQB®。然而,CB Science之前聘请了MaloneBailey LLP进行上市公司会计监督委员会(PCAOB)审计,并任命了足够的独立董事,这两个关键要求都需要考虑才能晋升。

"If accepted, uplisting to the OTCQB® would be a critically important step for the Company as we continue to execute our business plan," said Charles Martin, Chief Executive Officer of CB Scientific. "Additionally, achieving such an auspicious milestone will certainly better position us to meet required listing standards as we work towards achieving one of our longer-term objectives of becoming a Nasdaq Capital Markets-listed company," he added.

CB Science首席执行官查尔斯·马丁(Charles Martin)表示:“如果获得批准,进入OTCQB®对公司来说将是至关重要的一步,因为我们将继续执行我们的业务计划。”“此外,在我们努力实现成为纳斯达克资本市场(Nasdaq Capital Markets)上市公司这一较长期目标的过程中,实现这样一个吉祥的里程碑,肯定会使我们更好地达到所需的上市标准。”他补充说。

The Company believes that an uplist to the OTCQB® would provide enhanced investor benefits, including more comprehensive compliance requirements, higher reporting standards, and greater access to analyst coverage.

该公司相信,OTCQB®的上行将为投资者带来更大的好处,包括更全面的合规要求、更高的报告标准以及更多地接触分析师覆盖范围。

As additional new developments occur, CB Scientific plans to make timely announcements through press releases and regulatory filings to keep its shareholders, industry participants, and the public markets informed.

随着更多新情况的出现,世邦魏理仕计划通过新闻稿和监管文件及时发布公告,让其股东、行业参与者和公开市场随时了解情况。

About CB Scientific, Inc.
CB Scientific (https://cbscientificinc.com/), through its domestic and international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms provide improved compliance for patients at risk of abnormal heart rhythms, as well as more accurate information for physicians.

关于CB Science,Inc.世邦魏理仕(https://cbscientificinc.com/),)通过其国内和国际子公司,在非侵入性非侵入性心脏监护领域提供创新的产品和服务。我们的FDA和CE批准的EKG设备、基于云的交互式采集软件以及适用于iOS和Android平台的智能手机应用程序为有心律异常风险的患者提供了更好的遵从性,并为医生提供了更准确的信息。

Company Contact Information:
Telephone: (888) 225-0870
Email: General Inquiries: info@cbscientificinc.com
Investor Inquiries: Robert Hesse - dorchco.bh@gmail.com
Follow CBSC: Twitter, Facebook, Instagram, LinkedIn, YouTube, and Newsletter

公司联系信息:电话:(888)225-0870电子邮件:General Queries:info@cbSciences ficinc.com投资者咨询:Robert Hesse-dorchco.bh@gmail.com关注CBSC:Twitter、Facebook、Instagram、LinkedIn、YouTube和时事通讯

This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions, and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties, including, without limitation, the ability to obtain financing and regulatory and shareholder approval for anticipated actions.

这一信息披露可能包含“1995年私人证券诉讼法案”所涵盖的前瞻性陈述。这些前瞻性陈述涉及推出或增强我们的服务和产品的计划和时间,有关未来市场状况、供需状况的陈述,以及本新闻稿中包含的其他预期、意图和计划,这些都不是历史事实,涉及风险和不确定因素。我们对未来收入的预期取决于我们开发和供应产品和服务的能力,这些产品和服务可能不是我们今天生产的,而且符合规定的规格。在本新闻稿中使用的“计划”、“预期”、“相信”以及类似的表述通常代表前瞻性陈述。这些声明反映了我们目前的期望。它们受到许多风险和不确定性的影响,包括但不限于技术的变化和无处不在的市场的变化。本新闻稿包括1933年“证券法”第27A节和1934年“证券法”第27E节的含义内的前瞻性陈述。本新闻稿中包含的非历史事实的陈述可能被视为前瞻性陈述。投资者需要注意的是,前瞻性陈述本质上是不确定的。由于某些风险和不确定因素,包括但不限于获得融资以及监管机构和股东对预期行动的批准的能力,实际业绩和结果可能与本文预测或建议的大不相同。

SOURCE: CB Scientific, Inc.

资料来源:CB Science,Inc.


View source version on accesswire.com:
在accesswire.com上查看源代码版本:

https://www.accesswire.com/673054/CB-ScientificFiles-Application-to-Uplist-to-the-OTCQB-Venture-Market
Https://www.accesswire.com/673054/CB-ScientificFiles-Application-to-Uplist-to-the-OTCQB-Venture-Market

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发